Guidance, NICE advice and quality standards in development | Guidance

Showing 311 to 320 of 404

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]	Technology appraisal guidance	29 January 2025
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]	Technology appraisal guidance	TBC
Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]	Technology appraisal guidance	TBC
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]	Technology appraisal guidance	TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]	Technology appraisal guidance	TBC
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]	Technology appraisal guidance	TBC
Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention	Interventional procedures guidance	TBC
School-based interventions: physical and mental health and wellbeing promotion	Quality standard	TBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284	Technology appraisal guidance	TBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]	Technology appraisal guidance	TBC